Viking Therapeutics (VKTX) Earnings Date & Reports

Key Takeaways

• Viking Therapeutics (VKTX) is scheduled to report third-quarter 2026 results after the market close on Wednesday, October 28, 2026, with a conference call at 4:00 p.m. ET.
• Wall Street consensus calls for a net loss of about $1.06 per share, wider than the $0.81 per-share loss reported in the year-ago quarter.
• The company is expected to post zero revenue, reflecting its status as a clinical-stage biopharmaceutical company with no approved products yet.
• Investor attention will center on VK2735, Viking's dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) obesity drug candidate, including updates on the Phase 3 VANQUISH and SUNRISE trials.
• In its most recent quarter, Viking beat expectations, reporting a $1.10 per-share loss versus a roughly $1.21 consensus estimate.
• Analyst sentiment remains bullish, with 19 of 21 analysts rating the stock a Buy and a mean price target of $95.05.
• For more information on this ticker, explore additional pages for Major News, Today's Price Move, Price Targets, and Forecast.
• You can also discover new opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, best known for VK2735, its investigational obesity treatment. Because the company has no marketed drugs, quarterly financial results are secondary to clinical and pipeline milestones. The report arrives at a pivotal moment: Viking recently advanced oral VK2735 into Phase 3 with the SUNRISE-1 and SUNRISE-2 trials and has fully enrolled its injectable VANQUISH studies. With spending climbing as the company runs multiple late-stage programs, investors are watching both the pipeline's progress and the pace of cash consumption. The obesity market remains intensely competitive, making any update on differentiation and data timing a key catalyst for the stock.

Earnings Expectations

Analysts on average expect Viking to report a loss of about $1.06 per share for the third quarter of 2026, though estimates vary slightly across firms — Zacks Investment Research, for example, pegs the consensus at a loss of $1.00 per share. For a company with no commercial products, revenue is projected at zero. The expected loss compares with a $0.81 per-share loss in the same quarter a year earlier and a $1.10 per-share loss reported in the second quarter of 2026, when Viking beat the consensus estimate of roughly $1.21 per share.

For the full year 2026, analysts expect a loss of roughly $4.46 per share, with 2027 losses projected around $4.08 per share. While these headline figures matter for tracking cash burn, investors will likely pay far closer attention to management's commentary on clinical timelines than to the income statement itself.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking the biotech space alongside names like VKTX, it offers a practical way to surface relevant opportunities quickly. Explore the AI Screener to see how it can sharpen your market research.

Market Reaction and Investor Sentiment

Heading into the report, sentiment is mixed. Viking shares have lost roughly 31% year to date and trade well below their 52-week high of $43.15, reflecting a broader reset in investor enthusiasm for earlier-stage obesity drug developers. Even so, Wall Street's longer-term view remains constructive: 19 of 21 analysts rate the stock a Buy, with a mean price target of $95.05.

The market's near-term reaction will likely hinge less on the earnings per share (EPS) figure and more on pipeline news. Key risk factors include rising research and development (R&D) expenses tied to multiple Phase 3 trials, uncertainty around regulatory pathways, and intense competition from established and emerging players in the weight-loss market.

Forward Outlook and Key Factors to Monitor

Looking beyond the print, investors should watch several catalysts that could shape Viking's trajectory over the coming quarters. The most significant are data readouts from the fully enrolled VANQUISH-1 and VANQUISH-2 Phase 3 trials of injectable VK2735, which are anticipated in 2027. Positive results would be a major step toward potential commercialization.

The newly launched SUNRISE-1 and SUNRISE-2 trials for oral VK2735 will also be closely watched. These studies are smaller and shorter than the VANQUISH program, and enrollment progress could offer an early read on the oral formulation's development timeline.

Viking's maintenance dosing strategy is another area of interest. Recent data showed patients retained the large majority of their initial weight loss on less frequent dosing schedules, and the company has now begun the second part of that study to evaluate oral VK2735 alongside less-frequent injections. Results are expected in 2027.

Finally, investors will monitor cash runway and spending trends. Running several late-stage studies simultaneously is expensive, and management's guidance on how far the current cash position can fund operations will remain a focal point, alongside early progress on VK3019, Viking's investigational dual amylin and calcitonin receptor agonist.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations